NCT02799238View on ClinicalTrials.gov

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 14, 2019

Study Completion Date

February 24, 2020

Conditions

Glioblastoma

Interventions

BIOLOGICAL

ALECSAT

3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months

RADIATION

Radiotherapy

Radiotherapy 5 days/week for 6 weeks

DRUG

Temozolomide

Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks

Trial Locations (4)

55185

Ryhov hospital, Jönköping

Unknown

Sahlgrenska University Hospital, Gothenburg

221 85

Skånes university hospital, Lund

171 76

Karolinska University hospital, Stockholm

All Listed Sponsors

lead

CytoVac A/S

INDUSTRY

NCT02799238 - Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma | Biotech Hunter | Biotech Hunter